Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva head Schultz mixes generics with specialty

Executive Summary

Teva is merging its generics and branded ‘specialty’ operations into a single unit with immediate effect, as part of a restructuring led by the Israeli firm’s new president and chief executive officer, Kåre Schultz. Less than a month after he took the role, Schultz said the firm was taking “decisive and immediate action to address external pressures and internal inefficiencies”, after impairment charges wiped out US$6.1 billion of goodwill earlier this year, and the company faces a high debt burden in the wake of buying Actavis.

You may also be interested in...



Who’s Hired? Stada Makes Moves In Germany And Poland

Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Dr Reddy's Takes Action After Cyber-Attack

Dr Reddy’s says it has suffered a cyber-attack and has isolated “all data center services” so that it can take actions to mitigate the impact.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel